Screening for Gestational Diabetes Mellitus: A Systematic Review for the U.S. Preventive Services Task Force

  1. Teresa A. Hillier, MD, MS;
  2. Kimberly K. Vesco, MD, MPH;
  3. Kathryn L. Pedula, MS;
  4. Tracy L. Beil, MS;
  5. Evelyn P. Whitlock, MD, MPH; and
  6. David J. Pettitt, MD
  1. From Kaiser Permanente Northwest, Portland, Oregon, and Sansum Diabetes Research Institute, Santa Barbara, California.
    1. Figure 1.
      View larger version:
      Figure 1. Analytic framework.

      Key questions: 1) Does screening for gestational diabetes lead to a reduction in perinatal morbidity and mortality for mother or infant? A) After 24 weeks' gestation? B) During the first trimester and up to 24 weeks' gestation? 2) What are the sensitivities, specificities, reliabilities, and yields of current screening tests for gestational diabetes? A) After 24 weeks' gestation? B) During the first trimester and up to 24 weeks' gestation? 3) Does treatment of gestational diabetes lead to reduction in perinatal morbidity and mortality for mother or infant? A) After 24 weeks' gestation? B) During the first trimester and up to 24 weeks' gestation? 4) What are the adverse effects associated with screening for gestational diabetes? 5) What are the adverse effects associated with treatment of gestational diabetes? GDM = gestational diabetes mellitus; NICU = neonatal intensive care unit.

    2. Figure 2.
      View larger version:
      Figure 2. Search results by key question.

      USPSTF = U.S. Preventive Services Task Force. *Six of these articles are also included in the results from key question 3.

    Summary for Patients

    « Previous | Next Article »Table of Contents